| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1021406276 |
| P356 | DOI | 10.1007/S11906-016-0626-9 |
| P8608 | Fatcat ID | release_konxbmmicfdnxh6ylliqeah4le |
| P698 | PubMed publication ID | 26838033 |
| P5875 | ResearchGate publication ID | 292948225 |
| P50 | author | Carlos F. Lagos | Q38546932 |
| Cristian A Carvajal | Q58381808 | ||
| P2093 | author name string | Andrea Vecchiola | |
| Rene Baudrand | |||
| Carlos E Fardella | |||
| P2860 | cites work | Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors | Q79326169 |
| Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway | Q79520934 | ||
| A possible association between primary aldosteronism and a lower beta-cell function | Q81333341 | ||
| Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment | Q84059601 | ||
| High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension | Q84586295 | ||
| Effects of angiotensin-converting enzyme inhibition on leptin and adiponectin levels in essential hypertension | Q87104750 | ||
| Structural insights into aldosterone synthase substrate specificity and targeted inhibition | Q24309370 | ||
| Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity | Q26777180 | ||
| Cellular mechanisms of MR regulation of adipose tissue physiology and pathophysiology | Q26798415 | ||
| Obesity pharmacotherapy: current perspectives and future directions | Q26828559 | ||
| Aldosterone synthase inhibition in humans | Q27016157 | ||
| A unified nomenclature system for the nuclear receptor superfamily | Q28142509 | ||
| Mechanisms of mineralocorticoid action | Q28281657 | ||
| GPER mediates the inhibitory actions of estrogen on adipogenesis in 3T3-L1 cells through perturbation of mitotic clonal expansion | Q28509401 | ||
| Molecular mechanisms of human hypertension | Q32138445 | ||
| The metabolic syndrome | Q33569142 | ||
| Silencing of the mineralocorticoid receptor by ribonucleic acid interference in transgenic rats disrupts endocrine homeostasis | Q33642921 | ||
| Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension | Q33667283 | ||
| Aldosterone production and insulin resistance in healthy adults | Q33786853 | ||
| The sgk, an aldosterone-induced gene in mineralocorticoid target cells, regulates the epithelial sodium channel | Q33888851 | ||
| Mineralocorticoid receptor knockout mice: lessons on Na+ metabolism | Q33888855 | ||
| The role of aldosteronism in causing obesity-related cardiovascular risk | Q33995992 | ||
| Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin-angiotensin system | Q34150434 | ||
| Non-genomic actions of aldosterone: from receptors and signals to membrane targets. | Q34204736 | ||
| GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state | Q34366110 | ||
| Modulation of adiponectin as a potential therapeutic strategy | Q34408711 | ||
| Epigenetics: A New Bridge between Nutrition and Health | Q34591910 | ||
| Effects of aldosterone on insulin sensitivity and secretion | Q34614820 | ||
| Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its α-kinase domain | Q34949485 | ||
| Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. | Q35551235 | ||
| Control of aldosterone secretion: a model for convergence in cellular signaling pathways | Q35715226 | ||
| The multifaceted mineralocorticoid receptor | Q35906989 | ||
| Blood pressure response to angiotensin II is enhanced in obese Zucker rats and is attributed to an aldosterone-dependent mechanism | Q36252804 | ||
| Potassium as a link between insulin and the renin-angiotensin-aldosterone system | Q36272726 | ||
| Visceral adipose tissue: emerging role of gluco- and mineralocorticoid hormones in the setting of cardiometabolic alterations | Q36297722 | ||
| Mineralocorticoid-stimulating activity of adipose tissue | Q36324058 | ||
| Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice | Q36672857 | ||
| Angiotensin 1-7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model | Q36720577 | ||
| Abnormal aldosterone physiology and cardiometabolic risk factors | Q36737227 | ||
| Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines | Q37352865 | ||
| Corticosteroid receptors, macrophages and cardiovascular disease. | Q37374054 | ||
| Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. | Q37379344 | ||
| Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas | Q37616835 | ||
| Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects | Q37624307 | ||
| Aldosterone and arterial hypertension | Q37660912 | ||
| The kidneys and aldosterone/mineralocorticoid receptor system in salt-sensitive hypertension | Q37826130 | ||
| This is not Dr. Conn's aldosterone anymore. | Q37891697 | ||
| The renin-angiotensin-aldosterone system and glucose homeostasis | Q37924374 | ||
| Role of renin-angiotensin-aldosterone system in adipose tissue dysfunction | Q37998731 | ||
| Are there still healthy obese patients? | Q38034895 | ||
| Immune system alterations by aldosterone during hypertension: from clinical observations to genomic and non-genomic mechanisms leading to vascular damage | Q38099443 | ||
| Leptin-activity blockers: development and potential use in experimental biology and medicine | Q38151768 | ||
| Aldosterone's mechanism of action: roles of lysine-specific demethylase 1, caveolin and striatin | Q38166177 | ||
| Epigenetics and arterial hypertension: the challenge of emerging evidence. | Q38230822 | ||
| 20 years of leptin: insights into signaling assemblies of the leptin receptor | Q38234139 | ||
| An alternatively spliced rat mineralocorticoid receptor mRNA causing truncation of the steroid binding domain | Q38315131 | ||
| Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells | Q38330461 | ||
| Dynamic regulation of the angiotensinogen gene by DNA methylation, which is influenced by various stimuli experienced in daily life | Q38391270 | ||
| New perspectives on the development of antiobesity drugs | Q38397340 | ||
| Past and present of antiobesity agents: focus on monoamine modulators | Q38421011 | ||
| Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis. | Q38835940 | ||
| Dynamic CCAAT/enhancer binding protein-associated changes of DNA methylation in the angiotensinogen gene | Q39066928 | ||
| MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex | Q39128611 | ||
| Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction | Q39366285 | ||
| Renal target sites and the mechanism of action of aldosterone. | Q40106515 | ||
| Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects | Q40352252 | ||
| Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human | Q40611388 | ||
| Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. | Q40820510 | ||
| The mineralocorticoid receptor mediates aldosterone-induced differentiation of T37i cells into brown adipocytes. | Q40866064 | ||
| Crystal structures of the human adiponectin receptors | Q41099333 | ||
| MicroRNAs miR-124 and miR-135a are potential regulators of the mineralocorticoid receptor gene (NR3C2) expression | Q42150524 | ||
| Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway | Q42173694 | ||
| What Is the Role of the Adipocyte Mineralocorticoid Receptor in the Metabolic Syndrome? | Q42333961 | ||
| Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure | Q42457579 | ||
| Contribution of glucocorticoid-mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction | Q42799736 | ||
| Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. | Q42829877 | ||
| Insulin-sensitive obesity | Q43008676 | ||
| Aldosterone 'escape' vs 'breakthrough'. | Q43181273 | ||
| Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. | Q43233439 | ||
| Increased urinary aldosterone excretion is associated with subcutaneous not visceral, adipose tissue area in obese individuals: a possible manifestation of dysfunctional subcutaneous adipose tissue | Q43894263 | ||
| Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. | Q43945739 | ||
| Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study | Q44196283 | ||
| Oxidized products of linoleic acid stimulate adrenal steroidogenesis | Q44280066 | ||
| Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients | Q44415971 | ||
| Weight loss and the renin-angiotensin-aldosterone system | Q45209925 | ||
| Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells | Q45235702 | ||
| Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha. | Q45928244 | ||
| Aldosterone and metabolic dysfunction: an unresolved issue | Q46120249 | ||
| Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions | Q46370822 | ||
| Prevalence and characteristics of the metabolic syndrome in primary aldosteronism | Q46807615 | ||
| Relationship between adipocyte size and adipokine expression and secretion | Q47310274 | ||
| Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. | Q53183212 | ||
| Inducible renal principal cell-specific mineralocorticoid receptor gene inactivation in mice. | Q53262848 | ||
| Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor. | Q53555787 | ||
| GPER-1 and estrogen receptor-β ligands modulate aldosterone synthesis. | Q54326616 | ||
| Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice | Q56973407 | ||
| Rescue of the mineralocorticoid receptor knock-out mouse | Q59278413 | ||
| GPR30 Expression Is Required for the Mineralocorticoid Receptor–Independent Rapid Vascular Effects of Aldosterone | Q61772039 | ||
| Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart | Q71844423 | ||
| Effect of experimental potassium deficiency on glucose and insulin metabolism | Q72137255 | ||
| Vascular aldosterone in genetically hypertensive rats | Q73086441 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 20 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | Current Hypertension Reports | Q15746362 |
| P1476 | title | Aldosterone Production and Signaling Dysregulation in Obesity | |
| P478 | volume | 18 |
| Q94561367 | Eplerenone Implantation Improved Adipose Dysfunction Averting RAAS Activation and Cell Division |
| Q51273122 | Genomic and rapid effects of aldosterone: what we know and do not know thus far. |
| Q59327149 | Heritability and Genome-Wide Association Study of Plasma Cholesterol in Chinese Adult Twins |
| Q58760700 | Lipocalin-2 derived from adipose tissue mediates aldosterone-induced renal injury |
| Q26741152 | Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives |
| Q42367953 | Obesity-Related Hypertension in Children |
| Q55310756 | Physiological Aldosterone Concentrations Are Associated with Alterations of Lipid Metabolism: Observations from the General Population. |
| Q61813229 | Renal mineralocorticoid receptor expression is reduced in lipoatrophy |
| Q88104956 | Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome |
| Q48025446 | The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature. |
| Q47788950 | The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall |
Search more.